# 2019 Oncology **Annual Report**

(With statistical data from 2018)



### **Cancer Centers of Montana**

A department of St. James Healthcare

## Table of Contents

Learning About Us: SCL Health Cancer Centers of Montana at St. James Healthcare
SCL Health Oncology Leadership Welcome
SCL Health Oncology Service Line Goals
SCL Health   National Jewish Hospital   Centers of Excellence 6
Personalized Care and Clinical Research
Cancer Committees and Service Leadership
SCL Health Cancer Registry 9
Summary of Data 2018
Compliance Activity 13-14
How to Reach Us



### **Learning About Us** SCL Health Cancer Centers of Montana at St. James Healthcare

Our comprehensive cancer programs offer care from diagnosis and treatment through survivorship. Our entire cancer team focuses on whole-person care centered around our patients. We recognize cancer care is about more than fighting a disease. It's about helping patients and families adapt to new roles and ever- changing emotions while providing the information needed to understand treatment options. That is why we have leading-edge cancer treatment, the latest technologies, access to clinical studies and nationally renowned cancer doctors.

#### **Cancer Care patient Stories:**

We are proud to be able to share the experiences of some of the people we have cared for at SCL Health Cancer Centers of Colorado and Montana. Our hope is that their stories will inspire you, provide you with encouragement and a sense of community. You are not alone in your cancer journey. We have the expertise and will be with you every step of the way.

#### **Click here for stories**



## SCL Health Oncology Leadership Welcome



It has been a year of progress and growth for the SCL Health Cancer Centers of Colorado and Montana. We have welcomed new medical, radiation and surgical oncologists to our team. System-wide we joined the Strata Oncology network of health systems. This partnership provides our patients with the latest in molecular profiling of their cancers, at no cost to them. This gives their physicians information on the genetic make-up of those cancers to help direct treatment. In November we launched Oncology News and Notes, a quarterly newsletter highlighting people and events in our centers.

In Montana there has been continued growth of the oncology clinical research program at St. Vincent's and the launching of a clinical research program at St. James. At Holy Rosary in Miles City a newly renovated infusion center opened providing patients with increased comfort while receiving treatment. An exciting program was initiated across the region to increase lung cancer screenings for Native Americans. Low dose CT lung screening has been shown to reduce death from lung cancer in appropriately selected populations. Through a grant from George Washington University, our Montana SCL improvement initiative will endeavor to increase screenings and other healthcare services to the Crow and Northern Cheyenne tribes.

At St. Mary's in Grand Junction we welcomed Dr. Lucas Gilbride (radiation oncology) and Dr. Alicia Swink (medical oncology). In addition Dr. Joyce Sekheran took over the medical directorship of our breast cancer program. St. Mary's completed the remodel of the Breast Care Center, including the Wilma B. Bacon Mammography Center. The new look provides an improved atmosphere of tranquility and healing.

On the Front Range we have welcomed surgical oncologist, Dr. Parth Shah (Saint Joseph and Good Samaritan), medical oncologists Lovie Bey (Lutheran) and Ike Onwere (Platte Valley). Dr. Julie Carlson (radiation oncologist) relocated from St. Mary's to Lutheran Medical Center in Wheat Ridge. A monthly art therapy program was launched at the Good Samaritan Cancer Center with growing participation from patients and care-givers. The Platte Valley oncology program showed continued growth with the arrival of Dr. Ike Onwere and Sloan's Lake, our free standing clinic continued to provide services to oncology as well as non-oncology patients receiving infusions.

All of this occurred as we continued to see increased treatment options for individuals with cancer, utilizing specifically targeted drugs, and immune directed therapies. Together the cancer death rate continues to shrink and the number of cancer survivors increases.

#### Alan M. Miller MD, PhD Chief Medical Director of Oncology

### SCL Health Oncology Service Line Goals

SCL Health's oncology service line's primary goal is to be recognized as THE destination for cancer-related care and services for the Western Mountain States.

At SCL Health, we are devoted to putting the patients and their families first. We are committed to the prevention, screening, detection and treatment of cancers. Our goal is to ensure patients diagnosed with cancer can trust SCL Health for compassionate, comprehensive, wellcoordinated, high value, and quality cancer care.

#### **SCL Health Promotes:**

- Screening and cancer prevention
- Advanced treatment, technologies and services
- Cancer care close to home
- Precision medicine and targeted therapies
- Access to national and local clinical trials

Integrated therapies at each SCL Health facility offering cancer services is expected to be part of the system-wide network, providing comprehensive cancer care services and creating cancer care networks within each geographical location.

Our long-term goal is to extend the SCL Health Cancer Care Network beyond our facilities and into other communities building relationships with outstanding health care organizations, thus improving cancer care for more patients.



## SCL Health | National Jewish Health | Centers of Excellence

#### **National Jewish Health | SCL Health**



Jeffrey A. Kern, MD Chief, Oncology Division Vice-Chair, Department of Medicine National Jewish Health

Kudos to the National Jewish Health and the SCL Health thoracic oncology programs for being designated as a Lung Cancer Center of Excellence by the GO<sub>2</sub> Foundation for Lung Cancer, a new merger of the Bonnie J. Addario Lung Cancer Foundation (ALCF) and the Lung Cancer Alliance (LCA). The Bonnie J. Addario Lung Cancer Foundation and the Lung Cancer Alliance are two of the most effective and influential nonprofit organizations serving the lung cancer community now coming together as GO<sub>2</sub> The Foundation for Lung Cancer.

The Foundation has set the ambitious goal of turning lung cancer into a chronically managed disease through its work with its Centers of Excellence (COE). The philosophy behind lung cancer care by the National Jewish Health and

SCL Health thoracic oncology program and the GO<sub>2</sub> Foundation for Lung Cancer is shared in the belief that the best way to treat lung cancer is through coordinated, multi-disciplinary care across the full spectrum of the disease as it presents in each patient. The great majority of patients receive their lung cancer care at their local hospital or cancer center, by their local oncologists, so local COEs are where the greatest strides can be made on improving survival from lung cancer.

Certification by GO<sub>2</sub> as a COE is a great achievement by the thoracic oncology program, and recognizes the success in developing thoracic

oncology throughout the system and the outstanding care delivered to our patients. The National Jewish Health/SCL Health lung cancer COE is one of only 21 programs in the U.S. certified as a Center of Excellence, the only certified program in the region, and the only system certified in the U.S.

As a Center of Excellence, patients have access to our team of experts and our advanced technologies for all stages of care; from early detection, to diagnosis and treatment, to support throughout a patient's survivorship. In addition, the  $GO_2$  Foundation brings a number of services to our thoracic oncology program. Patient educational materials, internet discussions on lung cancer topics by patients and medical experts, and assistance with event planning to raise awareness of lung cancer are all available.

Recognition of our expert care was again recognized by US News and World Report, which ranked SCL Health Saint Joseph Hospital as High Performing in Lung Cancer Surgery. The GO<sub>2</sub> Foundation also recognizes our expertise, asking for our participation in last year's COE Summit panel discussions on molecular testing in lung cancer patients, and this year presenting our efforts in lung cancer early detection through lung cancer screening programs, and tracking of all nodules identified on CT scans as potential lung cancers.

We are proud to partner with the GO<sub>2</sub> Foundation for Lung Cancer and look forward to working together to bring our combined expertise to our lung cancer patients.

### Personalized Care and Clinical Research

Today's treatments are more personalized because we understand so much more about the biology of the disease. SCL Health continues to build on its commitment to person-centered care and transforming the patient experience through its partnership with Strata Oncology, Inc. Strata Oncology is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems. By partnering with the Strata Precision Oncology Network™ (the Network), SCL Health will be able to provide the benefits of the latest technology and clinical research in precision oncology to patients across Colorado and Montana.

Through the Network, SCL Health patients will benefit from Strata's precision oncology platform and comprehensive treatment program for personalized cancer care. Eligible cancer patients will have access to routine tumor molecular profiling, rapid interpretation of test results and the ability to participate in local precision therapy clinical trials as well as being treated with FDA approved targeted therapies.

"As our understanding of cancer becomes more complex, the advent of targeted therapies and immune-based therapies allow us to look at the genes that drive cancer. This has led to a whole new class of medications that enable us to treat cancer in a more precise way with potentially fewer side effects," said Alan Miller, M.D., Chief Medical Director of Oncology and Associate Chief Medical Director of Clinical Research for SCL Health. "In order to leverage these new treatments, we need to characterize the cancer right down to its genetic roots. As part of the Network, we are able to offer this characterization at no cost to the patient and the results will ultimately inform a more precise treatment plan."



SCL Health is dedicated to empowering cancer patients through providing access to proven therapies and the latest scientifically-proven outcomes. SCL Health is one of two health systems in Colorado and the only health system in Montana to be part of the Strata Precision Oncology Network<sup>™</sup> (strataoncology.com). This partnership will transform how patients find and access cutting-edge, quality cancer care in the Colorado-Montana region.

The SCL Health research department is dedicated to clinical research, with the goal being to provide the best possible outcomes for our patients. To accomplish this clinical research coordinators are available at our cancer centers to screen cancer patients for eligibility and discuss the clinical trial options available to the patient. At any time SCL Health has between 50 and 100 trials available in a broad range of cancer types. By the end of 2019 it is estimated that 500 patients will have participated in cancer clinical trials at SCL Health.

### **Cancer Committee and Service Leadership**

Cancer program success is dependent on the multidisciplinary cancer committee. Each Commission on Cancer accredited cancer center has a Cancer Committee that is responsible for goal setting, planning, initiating, implementing, evaluating, and strives to improve all cancer related activities. St. James Healthcare is working towards Commission on Cancer accreditation and meets quarterly.

Committee Role	Member Name	Committee Role	Member Name	
Required Members		Community Outreach Coordinator	Jerri Doyle	
Cancer Committee Chair	Marwan Massouh, MD		Kathryn Flint	
Diagnostic Radiologist	Hassan Massouh, MD	Clinical Research Coordinator	Tina Erhardt Heather Duyck	
Pathologist	Randy Shannon, MD David Smirnow, MD	Psychosocial Services Coordinator	Mary Ann Pendergast Eva Curry, NP	
Surgeon	Andrew Stevens, MD Frank Raiser, MD	Additional Members – Strongly Recom	•	
Medical Oncologist	Marwan Massouh, MD	Nurse Navigator	Jodi Huckins	
Radiation Oncologist	lan Gallaher, MD	Nutrition	Chloe Lundquist	
Cancer Liaison Physician	lan Gallaher, MD	Rehabilitation	Kelly Bond	
Cancer Program Administrator	Jerri Doyle	Pharmacy	Risik Rask	
Oncology Nurse	Kelly Thresher	Spiritual Care	John Uggetti	
	Mary Ann Pendergast	American Cancer Society	Kris Holmes	
Social Worker or Case Manager		VP, COO, and CNO	Nancy Hoyt	
Certified Tumor Registrar	Michele Webb	SCL Health VP Oncology	Donna Bowers	
Palliative Care Professional	Catherine Bieker	SCL Health Medical Director Oncology	Dr. Alan Miller	
Palliative Care Professional		SCL Health Senior Director Oncology	Denise Black-Andersen	
Genetic Counselor	Karen Stears	Sr. Director, Clinical Support Services	Karen Costello	
Cancer Conference Coordinator	Jamie Ritter			
Quality Improvement Coordinator	Aleisha Drakos			
Cancer Registry Quality Coordinator	Michele Webb Catherine Bieker			

### SCL Health Cancer Registry



**Catherine Bieker**,

Director

**BS-HCA, CTR, RHIT** Cancer Registry

#### **Cancer Registry Overview**

All new cancer diagnoses seen at St. James Healthcare are abstracted by the SCL Health Cancer Registry. These cases are entered, updated, and maintained in the SCL Health Cancer Registry database.

The SCL Health Cancer Registry abstracted 226 analytical cancer cases for St. James Healthcare in 2018. Analytical cases are newly diagnosed cancer cases that meet the following criteria. The cancer was; 1) diagnosed only, 2) diagnosed and treated, or 3) diagnosed elsewhere and treated at St. James Healthcare. The top cancer body sites in 2018 were; breast, lung, and prostate.

#### **Cancer Registry Data**

The state of Montana requires hospitals to report all new diagnosed cancer cases to the Montana Central Tumor Registry (MCTR). Submitted cases are called abstracts and consist of all of the patients' diagnostic workup, treatment, and recurrence information.

The MCTR combines any treatment received from facilities outside of the SCL Health system, de-identifies the abstracts, and submits that data to national databases where it is used for statistical and research purposes. By monitoring diagnosed cases and the treatments received, the state of Montana can develop prevention and screening programs for Montana's residents. Additionally, researchers can assess treatment for effectiveness with the goal of providing future cancer patients with improved treatment and outcomes. SCL Health's leadership and the SCL Health Oncology Service Line use the registry's data to ensure community and patient needs are being met and the highest quality of care is provided. Patient privacy laws are strictly adhered to throughout the entire reporting process.

#### **Cancer Registry Requirements**

The cancer registry is responsible for identifying all eligible cancer cases seen at SCL Health through an extensive medical record review process called case finding. Once an eligible case is identified Certified Tumor Registrars or CTRs, will abstract the required information. The medical record is reviewed, including diagnostic imaging, pathology reports, consultations, treatment summaries and follow up visits. The required information is entered into the SCL Health Cancer Registry Database, checked for quality and reported to the Montana Central Tumor Registry (MCTR).

## Summary of Data 2018

#### 2018 St. James Healthcare New Cancer Cases - Body Site by AJCC Stage Tabulation

This report includes 2018 analytical cases; those diagnosed and/or treated at Saint James Healthcare in 2018. New Diagnoses only, does not include recurrences.

Body Site Name	Number of Cases	Sex		AJCC Stage							
		Male	Female	0	I.	П	Ш	IV	Unk	N/A	
Overall Totals	226	116	110	9	56	37	24	53	17	30	
Oral Cavity	6	4	2	0	1	2	0	3	0	0	
Lip	1	0	1	0	1	0	0	0	0	0	
Tongue	2	2	0	0	0	1	0	1	0	0	
Oropharynx	0	0	0	0	0	0	0	0	0	0	
Hypopharynx	1	1	0	0	0	0	0	1	0	0	
Other	2	1	1	0	0	1	0	1	0	0	
Digestive System	31	20	11	0	2	9	8	5	5	2	
Esophagus	3	2	1	0	0	0	0	1	1	1	
Stomach	1	1	0	0	0	0	1	0	0	0	
Colon	8	5	3	0	0	4	2	1	1	0	
Rectum	7	6	1	0	0	2	3	1	1	0	
Anus/Anal Canal	3	0	3	0	0	1	2	0	0	0	
Liver	4	4	0	0	2	1	0	0	1	0	
Pancreas	3	1	2	0	0	1	0	2	0	0	
Other	2	1	1	0	0	0	0	0	1	1	
Respiratory System	32	17	15	0	6	1	2	19	4	0	
Nasal/Sinus	2	2	0	0	0	0	1	1	0	0	
Larynx	2	1	1	0	1	0	1	0	0	0	
Other	1	1	0	0	0	0	0	0	1	0	
Lung/Bronc-Small Cell	2	1	1	0	0	1	0	1	0	0	
Lung/Bronc-Non Small Cell	22	10	12	0	5	0	0	15	2	0	
Other Bronchus & Lung	3	2	1	0	0	0	0	2	1	0	

### Summary of Data 2018 (continued)

#### 2018 St. James Healthcare New Cancer Cases - Body Site by AJCC Stage Tabulation

This report includes 2018 analytical cases; those diagnosed and/or treated at Saint James Healthcare in 2018. New Diagnoses only, does not include recurrences.

Body Site Name	Number of Cases	Sex		AJCC Stage						
		Male	Female	0	1	П	Ш	IV	Unk	N/A
Overall Totals	226	116	110	9	56	37	24	53	17	30
Blood & Bone Marrow	8	6	2	0	0	0	0	1	1	6
Leukemia	5	3	2	0	0	0	0	1	1	3
Multiple Myeloma	3	3	0	0	0	0	0	0	0	3
Other	0	0	0	0	0	0	0	0	0	0
Bone	0	0	0	0	0	0	0	0	0	0
Connect/Soft Tissue	2	1	1	0	0	0	0	0	0	2
Skin	4	4	0	0	3	1	0	0	0	0
Melanoma	4	4	0	0	3	1	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	0
Breast	51	1	50	2	36	4	2	4	3	0
Female Genital	7	0	7	0	0	0	0	6	1	0
Cervix Uteri	1	0	1	0	0	0	0	1	0	0
Corpus Uteri	1	0	1	0	0	0	0	0	1	0
Ovary	4	0	4	0	0	0	0	4	0	0
Vulva	1	0	1	0	0	0	0	1	0	0
Other	0	0	0	0	0	0	0	0	0	0
Male Genital	35	35	0	0	4	19	3	7	2	0
Prostate	34	34	0	0	4	19	3	7	1	0
Testis	0	0	0	0	0	0	0	0	0	0
Other	1	1	0	0	0	0	0	0	1	0
Urinary System	21	16	5	7	4	0	6	3	1	0
Bladder	12	9	3	6	1	0	2	2	1	0
Kidney/Renal	8	6	2	0	3	0	4	1	0	0
Other	1	1	0	1	0	0	0	0	0	0

### Summary of Data 2018 continued

#### 2018 St. James Healthcare New Cancer Cases - Body Site by AJCC Stage Tabulation

This report includes 2018 analytical cases; those diagnosed and/or treated at Saint James Healthcare in 2018. New Diagnoses only, does not include recurrences.

Body Site Name	Number of Cases	S	Sex AJCC Stage				;			
		Male	Female	0	1	Ш	Ш	IV	Unk	N/A
Overall Totals	226	116	110	9	56	37	24	53	17	30
Brain & Cns	14	6	8	0	0	0	0	0	0	14
Brain (Benign)	1	1	0	0	0	0	0	0	0	1
Brain (Malignant)	6	3	3	0	0	0	0	0	0	6
Other	7	2	5	0	0	0	0	0	0	7
Endocrine	5	2	3	0	0	0	0	2	0	3
Thyroid	2	0	2	0	0	0	0	2	0	0
Other	3	2	1	0	0	0	0	0	0	3
Lymphatic System	7	2	5	0	0	1	3	3	0	0
Hodgkin's Disease	0	0	0	0	0	0	0	0	0	0
Non-Hodgkin's	7	2	5	0	0	1	3	3	0	0
Unknown Primary	3	2	1	0	0	0	0	0	0	3
Other/III-Defined	0	0	0	0	0	0	0	0	0	0

Data Source: 11/21/19; S.Sandoval, SCL Health Cancer Registry Database.

## 2019 St. James Healthcare Compliance Activity

#### **Stage III Colorectal Cancer**

Commission on Cancer Standard 4.6 - Monitoring Compliance with Evidence-Based Guidelines

Presented at Cancer Committee September 19, 2019

Each calendar year, the Cancer Committee designates a physician member to complete an in depth analysis to assess and verify that cancer program patients are evaluated and treated according to evidence-based national treatment guidelines, results are presented to Cancer Committee and documented in the minutes.

#### Scope of Study:

The goal of this study is to identify all cases of Stage III colorectal cancer treated at St. James cancer center during the 2018 calendar year and evaluate compliance of first line therapy with the standard of care per the current NCCN guidelines. The purpose for the study is to identify compliance with standard practices so that the Cancer Committee can be notified of whether patients with this disease are being treated appropriately at our institution.

#### **Case Selection:**

Case selection criteria was identified by the physician reviewer and data pulled from the SCL Cancer Registry database. All cases of colon, sigmoid, and rectal cancer, histology of adenocarcinoma and any grade, treated during the 2018 calendar year at St. James cancer center were identified. The medical record was then reviewed to identify those patients with Stage III disease and determine which treatment modalities were received.

Gender: Male or Female Age >= 18 years Accession Year: 2018 Class of Case: Analytic (class 10-22) Primary Site(s): Colon (C50.0-C50.9) and Rectum (C20.9) Histology: Adenocarcinoma (81403) Grade: Any Stage: Stage Group III

## Evidence-Based Guidelines and Standard of Care:

For colon and sigmoid colon cancer standards, the NCCN Guidelines, version 2.2019 for colon cancer, specifically the COL-3 pathway,

was referenced. For rectal cancer treatment standards, the NCCN Guidelines, version 2.2019 specifically, the REC-5 and REC-6 pathways, were referenced. (See References below). Cases were scored as "compliant" if the patient received or was offered the guidelinerecommended first line therapy.

#### Methodology:

A total of 14 cases of colorectal cancer were identified as having undergone treatment at St. James Cancer Center during the 2018 calendar year. Of these, six (6) cases were clinical or pathologic Stage Group III. Specifically, there were three (3) cases of Stage III rectal cancer, two (2) cases of Stage III sigmoid colon cancer, and one (1) case of colon cancer.

All three (3) cases of rectal cancer were treated with neoadjuvant combined modality chemotherapy and radiation followed by resection which is consistent with the NCCN guideline referenced above. The two (2) cases of sigmoid colon cancer treated with resection followed by adjuvant chemotherapy which is also consistent with the NCCN guideline. One (1) of these patients received adjuvant radiation therapy





**Ian Gallaher MD** Cancer Liaison Physician (CLP), Radiation Oncology

### 2019 St. James Healthcare Compliance Activity (continued)

as there was a positive surgical margin in the retroperitoneum. The single (1) case of colon cancer was treated with resection and was offered, but refused, adjuvant chemotherapy.

#### **Conclusions:**

During 2018, there were six (6) cases of Stage III colorectal cancer who received all or part of their treatment at St. James Cancer Center. There was 100% compliance with the recommended first-line therapy per the current NCCN guidelines. One (1) patient did not receive the recommended adjuvant chemotherapy, although it was offered, and refused by the patient.

**Recommendations:** As there was 100% compliance with the national guidelines, no further action or changes are necessary to the practice patterns for the treatment of stage III colorectal cancer. This can be attributed to excellent communication and care coordination both at our institution and with other members of the regional medical community. Efforts should be made to continue outreach and encouragement of attendance at local tumor conferences. Similar studies should be performed in the future to ensure that high-quality care and compliance are maintained for other disease entities especially those which require multimodal and multidisciplinary coordination.

#### **Physician Reviewer**

• Ian Gallaher MD, Cancer Liaison Physician (CLP), Radiation Oncology, St. James Healthcare, Butte MT


#### References

- Monitoring Compliance with Evidence-Based Guidelines, Standard 4.6. Cancer Program Standards Manual 2016, Commission on Cancer (CoC), American College of Surgeons (ACoS), Chicago, IL.
- Colon Cancer, version 2.2019. National Comprehensive Cancer Network (NCCN). https://www.nccn.org/professionals/ physician\_gls/pdf/colon.pdf. Accessed September 16, 2019.
- Rectal Cancer, version 2.2019. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician\_gls/ pdf/rectal.pdf. Accessed September 16, 2019.

### SCL Health Cancer Centers of Montana at St. James Healthcare, is dedicated

to provide exceptional care based on the latest medical knowledge and treatments.

Patients and their loved ones are provided with a full complement of support services. The services provided are centralized at each cancer center, making care convenient, efficient, effective and collaborative.





#### Cancer Centers of Montana at St. James Healthcare

 400 S Clark St., Butte, MT 59701
 Breas

 406-723-2999 | sclhealth.org
 406-7

**Breast Center** 406-723-2855